In Brief: Butenafine
This article was originally published in The Tan Sheet
Executive Summary
Butenafine: Foster City, Calif.-based Penederm's topical antifungal receives approval for OTC treatment of athlete's foot in Canada, the company announces. The product will be marketed by Schering-Plough, which intends to market the fungicide under one of its brand names: Lotrimin, Tinactin or Dr. Scholl's. Penederm says the launch will take place later this year. Penederm launched the ingredient earlier this year in the U.S. as Mentax, a Rx treatment for athlete's foot, ringworm and jock itch. Schering holds U.S. OTC rights for the ingredient but a switch will not occur for several years because of the licensing agreement...